Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Psoriasis of Scalp Clear all
Completed Phase 3 Interventional Results available

Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

NCT03721172
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
43
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 16, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis

NCT07340216
View directory record Official record
Conditions
Psoriasis
Interventions
ARQ-154 Foam 0.3%
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years to 12 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Bryant, Arkansas • Miami Lakes, Florida • Meridian, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 16, 2026, 2:08 PM EDT
Suspended Phase 2 Interventional

Study to Test the Effectiveness of a New Treatment for Scalp Psoriasis

NCT01368887
View directory record Official record
Conditions
Psoriasis
Interventions
DPS-102, Vehicle / Placebo, Calcipotriol Monotherapy, Nicotinamide Monotherapy
Drug · Other
Lead sponsor
DermiPsor, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • Brockton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 16, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis

NCT01139580
View directory record Official record
Conditions
Psoriasis
Interventions
Calcipotriene Foam, Vehicle Foam
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
26
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 16, 2026, 2:08 PM EDT
Completed Phase 3 Interventional

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

NCT03331523
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Calcipotriene/Betamethasone Dipropionate, Taclonex®, Placebo
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
31
States / cities
Encinitas, California • Fremont, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Sep 16, 2026, 2:08 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

NCT06095102
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
28
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Encinitas, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 16, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

NCT03123471
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
32
States / cities
Rogers, Arkansas • Fountain Valley, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Sep 16, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

NCT04128007
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Roflumilast foam 0.3%, Vehicle foam
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
31
States / cities
Rogers, Arkansas • Fremont, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Sep 16, 2026, 2:08 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Immune Spatial Features of Guselkumab Cutaneous Response

NCT05858632
View directory record Official record
Conditions
Psoriasis of Scalp
Interventions
Guselkumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 16, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis

NCT03122353
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Calcipotriene and betamethasone suspension, Taclonex, Placebo
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
34
States / cities
Hot Springs, Arkansas • Fremont, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 16, 2026, 2:08 PM EDT
Withdrawn No phase listed Observational

A Pilot Study to Explore the Role of Gut Flora in Psoriasis

NCT04099979
View directory record Official record
Conditions
Psoriasis, Psoriasis Vulgaris, Psoriasis Universalis, Psoriasis Face, Psoriasis Nail, Psoriatic Plaque, Psoriasis Diffusa, Psoriasis Punctata, Psoriasis Palmaris, Psoriasis Circinata, Psoriasis Annularis, Psoriasis Genital, Psoriasis of Scalp, Psoriasis Geographica
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 16, 2026, 2:08 PM EDT
Not listed Phase 4 Interventional

A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis

NCT01558310
View directory record Official record
Conditions
Scalp Psoriasis, Plaque Psoriasis
Interventions
Ustekinumab, Placebo
Drug
Lead sponsor
Paul Steven Yamauchi, MD, PhD
Individual
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2012 · Synced Sep 16, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Results available

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

NCT05969223
View directory record Official record
Conditions
Genital Psoriasis, Scalp Psoriasis
Interventions
Risankizumab, Placebo for Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 16, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product

NCT02933502
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
DSXS topical product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2018 · Synced Sep 16, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects

NCT02038569
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
LEO 80185 gel
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 17 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
San Diego, California • Tampa, Florida • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 16, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)

NCT01188928
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Calcipotriol plus betamethasone, Betamethasone-17,21-dipropionate, Calcipotriene, Topical suspension vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
59
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 16, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

NCT01690299
View directory record Official record
Conditions
Psoriasis, Psoriatic Arthritis
Interventions
Apremilast, Etanercept, Placebo tablet, Placebo injection
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
31
States / cities
Phoenix, Arizona • Bakersfield, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Sep 16, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

NCT05028582
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Roflumilast Foam 0.3%, Vehicle Foam
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
36
States / cities
Scottsdale, Arizona • Beverly Hills, California • Encinitas, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 16, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Results available

A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region

NCT05789576
View directory record Official record
Conditions
Psoriasis
Interventions
VTAMA (tapinarof) cream, 1%
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
10
States / cities
Macon, Georgia • Chicago, Illinois • Rockville, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 16, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris

NCT01707043
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Taclonex
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 16, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis

NCT05872256
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
0.045% Tazarotene/0.01% Halobetasol Lotion
Drug
Lead sponsor
Dermatology Consulting Services, PLLC
Network
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 16, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS

NCT02933528
View directory record Official record
Conditions
Psoriasis
Interventions
DSXS Topical product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 16, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Results available

Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp

NCT00881868
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
clobetasol propionate spray 0.05%, Vehicle spray
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Los Angeles, California • Evansville, Indiana • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Sep 16, 2026, 2:08 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis

NCT00279162
View directory record Official record
Conditions
Psoriasis
Interventions
Calcipotriene/betamethasone gel and ointment
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 16, 2026, 2:08 PM EDT